Browse HNF4A

Summary
SymbolHNF4A
Namehepatocyte nuclear factor 4, alpha
Aliases NR2A1; HNF4; TCF14; MODY; MODY1; FRTS4; HNF4a7; HNF4a8; HNF4a9; HNF4alpha; NR2A21; TCF; HNF4alpha10/11/12; T ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus.
Domain PF00104 Ligand-binding domain of nuclear hormone receptor
PF00105 Zinc finger
Function

Transcriptionally controlled transcription factor. Binds to DNA sites required for the transcription of alpha 1-antitrypsin, apolipoprotein CIII, transthyretin genes and HNF1-alpha. May be essential for development of the liver, kidney and intestine.

> Gene Ontology
 
Biological Process GO:0001558 regulation of cell growth
GO:0002790 peptide secretion
GO:0002791 regulation of peptide secretion
GO:0006352 DNA-templated transcription, initiation
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0006520 cellular amino acid metabolic process
GO:0006591 ornithine metabolic process
GO:0006805 xenobiotic metabolic process
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007369 gastrulation
GO:0007548 sex differentiation
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0009306 protein secretion
GO:0009410 response to xenobiotic stimulus
GO:0009743 response to carbohydrate
GO:0009746 response to hexose
GO:0009749 response to glucose
GO:0009755 hormone-mediated signaling pathway
GO:0009914 hormone transport
GO:0010470 regulation of gastrulation
GO:0010817 regulation of hormone levels
GO:0015833 peptide transport
GO:0016049 cell growth
GO:0019216 regulation of lipid metabolic process
GO:0023019 signal transduction involved in regulation of gene expression
GO:0023061 signal release
GO:0030072 peptide hormone secretion
GO:0030073 insulin secretion
GO:0030308 negative regulation of cell growth
GO:0030522 intracellular receptor signaling pathway
GO:0032844 regulation of homeostatic process
GO:0032846 positive regulation of homeostatic process
GO:0033500 carbohydrate homeostasis
GO:0034284 response to monosaccharide
GO:0042593 glucose homeostasis
GO:0042632 cholesterol homeostasis
GO:0042886 amide transport
GO:0043401 steroid hormone mediated signaling pathway
GO:0045926 negative regulation of growth
GO:0045995 regulation of embryonic development
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0048545 response to steroid hormone
GO:0050708 regulation of protein secretion
GO:0050796 regulation of insulin secretion
GO:0050817 coagulation
GO:0050878 regulation of body fluid levels
GO:0055088 lipid homeostasis
GO:0055090 acylglycerol homeostasis
GO:0055091 phospholipid homeostasis
GO:0055092 sterol homeostasis
GO:0060395 SMAD protein signal transduction
GO:0070328 triglyceride homeostasis
GO:0071383 cellular response to steroid hormone stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071466 cellular response to xenobiotic stimulus
GO:0090087 regulation of peptide transport
GO:0090276 regulation of peptide hormone secretion
GO:2000188 regulation of cholesterol homeostasis
GO:2000189 positive regulation of cholesterol homeostasis
Molecular Function GO:0000979 RNA polymerase II core promoter sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001046 core promoter sequence-specific DNA binding
GO:0001047 core promoter binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001085 RNA polymerase II transcription factor binding
GO:0001102 RNA polymerase II activating transcription factor binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003705 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding
GO:0003707 steroid hormone receptor activity
GO:0004879 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding
GO:0005504 fatty acid binding
GO:0008134 transcription factor binding
GO:0031406 carboxylic acid binding
GO:0033293 monocarboxylic acid binding
GO:0033613 activating transcription factor binding
GO:0043168 anion binding
GO:0098531 transcription factor activity, direct ligand regulated sequence-specific DNA binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04152 AMPK signaling pathway
Reactome R-HSA-1266738: Developmental Biology
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-383280: Nuclear Receptor transcription pathway
R-HSA-186712: Regulation of beta-cell development
R-HSA-210745: Regulation of gene expression in beta cells
Summary
SymbolHNF4A
Namehepatocyte nuclear factor 4, alpha
Aliases NR2A1; HNF4; TCF14; MODY; MODY1; FRTS4; HNF4a7; HNF4a8; HNF4a9; HNF4alpha; NR2A21; TCF; HNF4alpha10/11/12; T ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HNF4A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolHNF4A
Namehepatocyte nuclear factor 4, alpha
Aliases NR2A1; HNF4; TCF14; MODY; MODY1; FRTS4; HNF4a7; HNF4a8; HNF4a9; HNF4alpha; NR2A21; TCF; HNF4alpha10/11/12; T ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HNF4A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolHNF4A
Namehepatocyte nuclear factor 4, alpha
Aliases NR2A1; HNF4; TCF14; MODY; MODY1; FRTS4; HNF4a7; HNF4a8; HNF4a9; HNF4alpha; NR2A21; TCF; HNF4alpha10/11/12; T ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HNF4A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3690.333
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0680.922
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.6940.259
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1510.874
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6080.667
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.10.478
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-1.230.276
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2990.878
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-2.4470.212
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.3330.835
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2180.919
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.8780.0221
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HNF4A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.75.5-1.81
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.76.8-3.11
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolHNF4A
Namehepatocyte nuclear factor 4, alpha
Aliases NR2A1; HNF4; TCF14; MODY; MODY1; FRTS4; HNF4a7; HNF4a8; HNF4a9; HNF4alpha; NR2A21; TCF; HNF4alpha10/11/12; T ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HNF4A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHNF4A
Namehepatocyte nuclear factor 4, alpha
Aliases NR2A1; HNF4; TCF14; MODY; MODY1; FRTS4; HNF4a7; HNF4a8; HNF4a9; HNF4alpha; NR2A21; TCF; HNF4alpha10/11/12; T ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HNF4A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HNF4A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHNF4A
Namehepatocyte nuclear factor 4, alpha
Aliases NR2A1; HNF4; TCF14; MODY; MODY1; FRTS4; HNF4a7; HNF4a8; HNF4a9; HNF4alpha; NR2A21; TCF; HNF4alpha10/11/12; T ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HNF4A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHNF4A
Namehepatocyte nuclear factor 4, alpha
Aliases NR2A1; HNF4; TCF14; MODY; MODY1; FRTS4; HNF4a7; HNF4a8; HNF4a9; HNF4alpha; NR2A21; TCF; HNF4alpha10/11/12; T ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HNF4A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHNF4A
Namehepatocyte nuclear factor 4, alpha
Aliases NR2A1; HNF4; TCF14; MODY; MODY1; FRTS4; HNF4a7; HNF4a8; HNF4a9; HNF4alpha; NR2A21; TCF; HNF4alpha10/11/12; T ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HNF4A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHNF4A
Namehepatocyte nuclear factor 4, alpha
Aliases NR2A1; HNF4; TCF14; MODY; MODY1; FRTS4; HNF4a7; HNF4a8; HNF4a9; HNF4alpha; NR2A21; TCF; HNF4alpha10/11/12; T ......
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HNF4A collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting HNF4A.
ID Name Drug Type Targets #Targets
DB03017Lauric AcidSmall MoleculeADH5, C8G, GLTP, GM2A, HNF4A, LTF, LY96, PLA2G2A, PLA2G2D, PPARA, ......12
DB05447AVI-4557Small MoleculeHNF4A1
DB08231Myristic acidSmall MoleculeABL1, ARF1, ARF6, ECI2, FKBP1A, GM2A, GUCA1A, HNF4A, INS, LY96, NC ......20